Compare Monolithic Power Systems Inc (MPWR) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monolithic Power Systems Inc vs GeneDx Holdings Corp — how do they compare? Monolithic Power Systems Inc trades at $1,368.41 (market cap $67.32B), while GeneDx Holdings Corp trades at $67.71 (market cap $2.02B). The key difference: Monolithic Power Systems Inc is far larger — about 33.3× GeneDx Holdings Corp's market cap, and Monolithic Power Systems Inc pays a 0.58% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Monolithic Power Systems Inc for 25 Days and GeneDx Holdings Corp for 19 Days on average.
| MPWR | WGS | |
|---|---|---|
Market Cap | $67.32B | $2.02B |
Volume | 826,960 | 734,640 |
Sector | Technology | Health |
52-Week High | $1.69K | $167.51 |
52-Week Low | $856.96 | $34.51 |
Typical Hold Time | 25 Days | 19 Days |
Enterprise Value | $65.92B | $2.05B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MPWR trades at $1,425.98, down 3.24% today but maintains strong technical momentum with bullish moving averages and key support at $1,417. The company demonstrates robust fundamentals with 24.5% net margins and consistent earnings beats, while expanding manufacturing capacity through the GlobalFoundries partnership announced September 9, 2026. Analyst sentiment remains overwhelmingly positive with 88% buy ratings and a $1,830 consensus price target representing 28% upside potential.
MPWR presents compelling growth exposure to AI infrastructure demand but carries premium valuation risks. The stock's 83.6 P/E ratio requires sustained high growth execution, while insider selling and competitive pressures warrant monitoring. Current technical positioning near pivot point resistance at $1,427 suggests near-term consolidation before potential breakout toward analyst targets.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
